buyWeak cluster of 410b5-1 plan
Jones James bought $1,755 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 1,506 shares at an average of $1.17, traded Nov 1, 2024, filed Dec 5, 2024.
Conviction score
20Value
$1,755
1,506 shares
Holdings after
39,377
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-24-050111, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.15 | $87 | 37,947 | Dec 5, 2024 |
| Nov 4, 2024 | POpen-market purchase Common Stock10b5-1 | +49 | $1.17 | $57 | 37,996 | Dec 5, 2024 |
| Nov 5, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.20 | $91 | 38,072 | Dec 5, 2024 |
| Nov 6, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.20 | $91 | 38,148 | Dec 5, 2024 |
| Nov 7, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.17 | $89 | 38,224 | Dec 5, 2024 |
| Nov 8, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.18 | $90 | 38,300 | Dec 5, 2024 |
| Nov 11, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.20 | $91 | 38,376 | Dec 5, 2024 |
| Nov 12, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.20 | $91 | 38,452 | Dec 5, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.20 | $91 | 38,528 | Dec 5, 2024 |
| Nov 14, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.19 | $90 | 38,604 | Dec 5, 2024 |
| Nov 15, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.17 | $89 | 38,680 | Dec 5, 2024 |
| Nov 18, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.18 | $90 | 38,756 | Dec 5, 2024 |
| Nov 19, 2024 | POpen-market purchase Common Stock10b5-1 | +76 | $1.15 | $87 | 38,832 | Dec 5, 2024 |
| Nov 20, 2024 | POpen-market purchase Common Stock10b5-1 | +85 | $1.13 | $96 | 38,917 | Dec 5, 2024 |
| Nov 21, 2024 | POpen-market purchase Common Stock10b5-1 | +85 | $1.09 | $93 | 39,002 | Dec 5, 2024 |
| Nov 22, 2024 | POpen-market purchase Common Stock10b5-1 | +75 | $1.07 | $80 | 39,077 | Dec 5, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock10b5-1 | +75 | $1.09 | $82 | 39,152 | Dec 5, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stock10b5-1 | +75 | $1.11 | $83 | 39,227 | Dec 5, 2024 |
| Nov 27, 2024 | POpen-market purchase Common Stock10b5-1 | +75 | $1.15 | $86 | 39,302 | Dec 5, 2024 |
| Nov 29, 2024 | POpen-market purchase Common Stock10b5-1 | +75 | $1.32 | $99 | 39,377 | Dec 5, 2024 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $8,209 | 4,716 | |
| 25Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,318 | 769 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Jones James director | $1,318 | 769 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Young Caroline director | $256 | 154 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $9,348 | 8,029 | |
| 25Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,755 | 1,506 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Young Caroline director | $755 | 647 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth director | $9,106 | 7,107 | |
| 20Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J Chairman and CEO | $1,827 | 1,426 | |
| 15Weak | buy 410b5-1 | CPIX CUMBERLAND PHARMACEUTICALS INC | Jones James director | $1,827 | 1,426 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.